| Literature DB >> 29358332 |
Romain A Colas1, Anthony W Ashton2, Shankar Mukherjee3, Jesmond Dalli1, Oscar B Akide-Ndunge3, Huan Huang3, Mahalia S Desruisseaux3,4, Fangxia Guan3,5, Linda A Jelicks6, Fabiane Matos Dos Santos3, Jyothi Nagajyothi7, Michael A Zingman3, Jinet Reyes3, Louis M Weiss3,4, Charles N Serhan1, Herbert B Tanowitz8,4.
Abstract
Trypanosoma cruzi is a protozoan parasite that causes Chagas disease (CD). CD is a persistent, lifelong infection affecting many organs, most notably the heart, where it may result in acute myocarditis and chronic cardiomyopathy. The pathological features include myocardial inflammation and fibrosis. In the Brazil strain-infected CD-1 mouse, which recapitulates many of the features of human infection, we found increased plasma levels of resolvin D1 (RvD1), a specialized proresolving mediator of inflammation, during both the acute and chronic phases of infection (>100 days postinfection) as determined by enzyme-linked immunosorbent assay (ELISA). Additionally, ELISA on lysates of trypomastigotes of both strains Tulahuen and Brazil revealed elevated levels of RvD1 compared with lysates of cultured epimastigotes of T. cruzi, tachyzoites of Toxoplasma gondii, trypomastigotes of Trypanosoma brucei, cultured L6E9 myoblasts, and culture medium containing no cells. Lysates of T. cruzi-infected myoblasts also displayed increased levels of RvD1. Lipid mediator metabolomics confirmed that the trypomastigotes of T. cruzi produced RvD1, RvD5, and RvE2, which have been demonstrated to modulate the host response to bacterial infections. Plasma RvD1 levels may be both host and parasite derived. Since T. cruzi synthesizes specialized proresolving mediators of inflammation, as well as proinflammatory eicosanoids, such as thromboxane A2, one may speculate that by using these lipid mediators to modulate its microenvironment, the parasite is able to survive.Entities:
Keywords: Chagas disease; Trypanosoma cruzi; eicosanoids; host-parasite relationship; immune modulation; inflammation; resolvin; resolvin D1; resolvin D5; resolvin E2; resolvins
Mesh:
Substances:
Year: 2018 PMID: 29358332 PMCID: PMC5865043 DOI: 10.1128/IAI.00688-17
Source DB: PubMed Journal: Infect Immun ISSN: 0019-9567 Impact factor: 3.441